RxSight Files 8-K on Financial Condition; Signals Upcoming Update
Ticker: RXST · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1111485
| Field | Detail |
|---|---|
| Company | Rxsight, Inc. (RXST) |
| Form Type | 8-K |
| Filed Date | Jan 8, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: financial-condition, 8-K, corporate-filing
TL;DR
**RxSight just filed an 8-K about its financials, so expect new numbers soon.**
AI Summary
RxSight, Inc. filed an 8-K on January 8, 2024, reporting an event that occurred on January 7, 2024, related to its results of operations and financial condition. This filing is a standard disclosure indicating that the company is providing an update on its financial performance, likely ahead of a more detailed earnings report. For investors, this matters because it signals that new financial information is being made public, which could influence the stock price (RXST) depending on whether the news is positive or negative.
Why It Matters
This filing indicates that RxSight is about to release or has just released new financial information, which is crucial for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — This 8-K is a procedural filing indicating an upcoming or recent financial disclosure, not a specific event that inherently carries high risk.
Analyst Insight
A smart investor would monitor RxSight's (RXST) news feed closely for the actual financial results that this 8-K foreshadows, as those details will be the true catalyst for stock movement.
Key Players & Entities
- RxSight, Inc. (company) — the registrant filing the 8-K
- January 07, 2024 (date) — date of the earliest event reported
- January 08, 2024 (date) — date the 8-K was filed
- 001-40690 (other) — Commission File Number for RxSight, Inc.
- RXST (other) — trading symbol for RxSight, Inc. Common Stock
- The Nasdaq Stock Market LLC (other) — exchange where RxSight, Inc. Common Stock is registered
Forward-Looking Statements
- RxSight, Inc. will release more detailed financial results or an earnings report shortly after this 8-K filing. (RxSight, Inc.) — high confidence, target: Q1 2024
- The stock price of RXST will react to the content of the upcoming financial disclosure. (RXST) — medium confidence, target: within 1 week of disclosure
FAQ
What is the purpose of this 8-K filing by RxSight, Inc.?
This 8-K filing, dated January 8, 2024, is a 'Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934' and specifically includes 'ITEM INFORMATION: Results of Operations and Financial Condition', indicating it's to disclose material information about the company's financial performance.
When did the earliest event reported in this 8-K occur?
The 'Date of Report (Date of earliest event reported)' for this 8-K filing is January 07, 2024.
What is RxSight, Inc.'s trading symbol and where is its common stock registered?
RxSight, Inc.'s trading symbol is RXST, and its Common Stock, with a par value of $0.001 per share, is registered on The Nasdaq Stock Market LLC.
What is the business address of RxSight, Inc. as stated in the filing?
The business address of RxSight, Inc. is 100 Columbia, Suite 120, Aliso Viejo, California, 92656.
Is RxSight, Inc. considered an emerging growth company according to this filing?
The filing includes a checkbox 'Indicate by check mark whether the registrant is an emerging growth company...', but the box is not checked (indicated by '☐'), implying that RxSight, Inc. does not consider itself an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Filing Stats: 502 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-01-08 06:01:18
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share RXST The Nasdaq Stock Mar
Filing Documents
- rxst-20240107.htm (8-K) — 39KB
- rxst-ex99_1.htm (EX-99.1) — 19KB
- img261313502_0.jpg (GRAPHIC) — 4KB
- 0000950170-24-002636.txt ( ) — 179KB
- rxst-20240107_pre.xml (EX-101.PRE) — 9KB
- rxst-20240107.xsd (EX-101.SCH) — 2KB
- rxst-20240107_lab.xml (EX-101.LAB) — 12KB
- rxst-20240107_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On January 7, 2024, RxSight, Inc. (the “Company”) issued a press release announcing certain preliminary unaudited fourth quarter and full-year 2023 financial and operational results. A copy of the press release is furnished herewith as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information furnished in this Current Report on Form 8-K under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or in any filing under the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit number Description 99.1 Press Release dated January 7, 2024. 104 Cover Page Interactive Data File (embedded within the inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. RxSight, Inc. Date: January 8, 2024 By: /s/ Shelley Thunen Name: Shelley Thunen Title: Chief Financial Officer